课题基金 / 基金详情

Targeted Covalent Pentafluorobenzene Sulfonamide-Based Afatinib Drug for Treating Breast Cancer

Targeted Covalent Pentafluorobenzene Sulfonamide-Based Afatinib Drug for Treating Breast Cancer
靶向共价五氟苯磺酰胺基阿法替尼药物治疗乳腺癌
批准号：
428860
负责人：
Hekmat Merna
金额：
$1.27万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-12-01 至 2020-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=428860&lang=en
关键词：
Afatinib Drug Biophysical Assay Breast Cancer Covalent Inhibitors Drug Discovery Electrophilic Tuning Epidermal Growth Factor Receptor Kinases Nucleophilic Aromatic Substitution Pentafluorobenzene Sulfonamide

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
"Breast cancer is a common malignancy in Canadian women accounting for approximately 14 deaths daily. Although there have been several advancements in treatments, current drugs are plagued by resistance mechanisms and off-target effects which leads to hig
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金